Stephen A Haggarty

Address:

296 Columbia St APT 4C, Brooklyn, NY 11231

Phone:

347 410-5876

VIN:

KMHDU46D97U233834

Make:

HYUNDAI

Model:

ELANTRA

Year:

2007

US Patent:

8088951, Jan 3, 2012

Filed:

Nov 30, 2007

Appl. No.:

11/998834

Inventors:

Andre Fischer - Goettingen, DE
Stephen Haggarty - Dorchester MA, US
Weiping Tang - Middleton WI, US
Stuart L. Schreiber - Boston MA, US

Assignee:

Massachusetts Institute of Technology - Cambridge MA
The General Hospital Corporation - Boston MA
President and Fellows of Harvard College - Cambridge MA

International Classification:

C07C 233/00

US Classification:

564123, 530300

Abstract:

The invention relates to methods and products for enhancing and improving recovery of lost memories. In particular the methods are accomplished through the increase of histone acetylation.

US Patent:

8178579, May 15, 2012

Filed:

Jul 17, 2007

Appl. No.:

11/879466

Inventors:

Stuart L. Schreiber - Boston MA, US
Scott M. Sternson - New York NY, US
Jason C. Wong - Cambridge MA, US
Christina M. Grozinger - Urbana IL, US
Stephen J. Haggarty - Somerville MA, US
Kathryn M. Koeller - Seattle WA, US

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

A61K 31/425
C07D 317/00

US Classification:

514452, 549369

Abstract:

In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I):.

US Patent:

8263547, Sep 11, 2012

Filed:

May 28, 2009

Appl. No.:

12/474229

Inventors:

Yingwei Mao - Arlington MA, US
Jon Madison - Newton MA, US
Stephen J. Haggarty - Dorchester MA, US

Assignee:

Massachusetts Institute of Technology - Cambridge MA
The General Hospital Corporation - Boston MA

International Classification:

A61K 38/00
C07K 5/00
G01N 33/53
C12Q 1/00

US Classification:

514 11, 530300, 530839, 435 71, 435 4

Abstract:

The invention relates to methods of treating neurological disorders in a subject, by activating a DISC1 pathway. Methods of promoting neurogenesis in adult neural progenitor cells, enhancing nerve generation and treating GSK3 disorders as well as related compositions are also provided.

US Patent:

8563615, Oct 22, 2013

Filed:

Nov 1, 2010

Appl. No.:

12/917402

Inventors:

Ji-Song Guan - Beijing, CN
Stephen J. Haggarty - Dorchester MA, US
Edward Holson - Newton Highlands MA, US
Florence Wagner - Ashland MA, US
Johannes Graeff - Waban MA, US

Assignee:

Massachusetts Institute of Technology - Cambridge MA
The Broad Institute, Inc. - Cambridge MA
Massachusetts General Hospital - Boston MA

International Classification:

A01N 37/18
A01N 33/18
A01N 33/24
A61K 31/165
A61K 31/12
C07C 233/00
C07C 235/00
C07C 237/00

US Classification:

514617, 514676, 514688, 564161

Abstract:

The invention relates to methods and compositions for promoting cognitive function and/or treating cognitive function disorders and impairments. In particular the methods are accomplished by administering to a subject CI-994 or dinaline or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof.

US Patent:

20040072849, Apr 15, 2004

Filed:

Jul 17, 2003

Appl. No.:

10/621276

Inventors:

Stuart Schreiber - Boston MA, US
Scott Sternson - New York NY, US
Jason Wong - Cambridge MA, US
Christina Grozinger - Urbana IL, US
Stephen Haggarty - Somerville MA, US
Kathryn Koeller - Seattle WA, US

International Classification:

A61K031/52
A61K031/506
A61K031/335

US Classification:

514/263230, 514/269000, 514/452000, 544/269000, 544/310000

Abstract:

In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I): and pharmaceutically acceptable derivatives thereof, wherein R, R, R, n, X and Y are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. The present invention further provides compounds capable of inhibiting histone deacetylatase activity and methods for treating disorders regulated by histone deacetylase activity (e.g., cancer and protozoal infections) comprising administering a therapeutically effective amount of a compound of formula (I) to a subject in need thereof. The present invention additionally provides methods for modulating the glucose-sensitive subset of genes downstream of Ure2p. The present invention also provides methods for preparing compounds of the invention.

US Patent:

20060239909, Oct 26, 2006

Filed:

Mar 22, 2006

Appl. No.:

11/386959

Inventors:

Kenneth Anderson - Wellesley MA, US
James Bradner - Cambridge MA, US
Edward Greenberg - Newton MA, US
Teru Hideshima - Brookline MA, US
Nicholas Kwiatkowski - Auburn MA, US
Ralph Mazitschek - Boston MA, US
Stuart Schreiber - Boston MA, US
Jared Shaw - Cambridge MA, US
Stephen Haggarty - Boston MA, US

International Classification:

A61K 51/00
A61K 39/395
A61K 33/36

US Classification:

424001490, 424155100, 424623000

Abstract:

The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.

US Patent:

20080311589, Dec 18, 2008

Filed:

Apr 21, 2008

Appl. No.:

12/107042

Inventors:

Brent R. Stockwell - Boston MA, US
Stuart L. Schreiber - Boston MA, US
Timothy J. Mitchison - Brookline MA, US
Tarun M. Kapoor - Cambridge MA, US
Thomas Mayer - Brookline MA, US
Stephen J. Haggarty - Somerville MA, US

International Classification:

G01N 33/53

US Classification:

435 71

Abstract:

The present invention provides a system for high-throughput analysis of chemical compounds. Assays are performed in a high density platform, and compounds having pre-determined desirable effects are identified. Preferably, the compounds have biological effects, more preferably, the assays and detection are performed on whole cells.

US Patent:

20100075926, Mar 25, 2010

Filed:

Jul 23, 2009

Appl. No.:

12/508481

Inventors:

Stephen J. Haggarty - Dorchester MA, US
Dohoon Kim - Somerville MA, US

International Classification:

A61K 31/675
A61K 31/663
A61K 31/662
A61K 31/55
A61P 9/10
A61K 31/352
A61K 31/195
A61K 31/16
A61K 31/138
C07D 223/16
C07D 311/78
C07D 311/02
C07C 229/28
C07C 237/06
C07C 215/20
C07F 9/02
C07F 9/28

US Classification:

514 82, 514 89, 514108, 514114, 51421702, 514453, 514456, 514567, 514616, 514653, 540595, 549381, 549403, 562444, 564153, 564355, 568 14, 568 15

Abstract:

The invention provides methods and compounds for the treatment of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (Amyotrophic Lateral Sclerosis), traumatic brain injury, ischemic brain injury or a stroke. In one aspect the compounds are HDAC1 activators. Exemplary HDAC1 activators include metal chelators, iron chelators, deferoxamin, flavonoids, compounds comprising a catechol moity, ginkgetin K, Chembridge 5104434, sciadopilysin, tetrahydrogamboic acid, TAM-11, LY 235959, CGS 19755, SK&F 97541, etidronic acid, levonordefrin, methyldopa, ampicillin trihydrate, D-aspartic acid, gamma-D-glutamylaminomethylsulfonic acid, phenazopyridine to hydrochloride, oxalamine citrate salt, podophyllotoxin, SK&F 97541, (+-)-4-amino-3-(5-chloro-2-thienyl)-butanoic acid, (RS)-(tetrazol-5-yl) glycine, R(+)-SKF-81297, gambogic acid, and derivatives thereof.